INM
InMed Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$1.99M
P/E Ratio
—
EPS
$-2.88
Beta
0.52
52W High
$5.50
52W Low
$0.57
50-Day MA
$0.87
200-Day MA
$1.73
Dividend Yield
—
Profit Margin
-170.10%
Forward P/E
—
PEG Ratio
—
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.
Fundamentals
| Revenue (TTM) | $4.51M |
| Gross Profit (TTM) | $1.34M |
| EBITDA | $-7.63M |
| Operating Margin | -258.60% |
| Return on Equity | -97.20% |
| Return on Assets | -49.80% |
| Revenue/Share (TTM) | $1.72 |
| Book Value | $3.42 |
| Price-to-Book | 0.21 |
| Price-to-Sales (TTM) | 0.44 |
| EV/Revenue | 0.282 |
| EV/EBITDA | 0.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -26.20% |
| Shares Outstanding | $2.92M |
| Float | $2.09M |
| % Insiders | 0.12% |
| % Institutions | 9.28% |
Data last updated: 4/8/2026